G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
118 hedge funds and large institutions have $343M invested in G1 Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
18% more funds holding
Funds holding: 100 → 118 (+18)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less capital invested
Capital invested by funds: $699M → $343M (-$356M)
100% less call options, than puts
Call options by funds: $2K | Put options by funds: $1.76M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$16.6M |
| 2 |
Goldman Sachs
New York
|
+$11.6M |
| 3 |
Millennium Management
New York
|
+$9.18M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.86M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$3.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.6M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$21.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.99M |
| 4 |
JP Morgan Chase
New York
|
-$6.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.53M |
GTHX Hedge Fund Activity: Q3 2020 in Review
118 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2020, worth a combined $343M — down 51% from $699M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new GTHX positions and 7 closed out — a net gain of 19 holders — while 39 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $16.6M. The largest seller was Fidelity Investments, cutting an estimated $22.6M.
- 118 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2020, up from 100 in Q2 2020.
- Funds reported $343M of G1 Therapeutics, Inc. Common Stock stock for Q3 2020, down 51% quarter-over-quarter.
- 26 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2020 and 7 closed out, a net change of +19 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2020 was State Street, an estimated $16.6M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2020 was Fidelity Investments, an estimated $22.6M sold.
Based on aggregated 13F filings for Q3 2020.